


下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEXMD8-87Cat. No.: HY-15811CAS No.: 1234480-46-6Synonyms: ACK1-B19分式: CHNO分量: 445.52作靶點(diǎn): Tyrosinase作通路: Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 26 mg/mL (58.3
2、6 mM)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (4.67 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.08 mg/mL (4.67 mM); Suspended solution; Need ultrasonicBIOLOGICAL ACTIVITY物活性 XMD8-87種有效的TNK2抑制劑
3、,對(duì)于D163E和R806Q突變體的IC50值分別為38和113 nM。IC50 & Target IC50: 38 nM (TNK2, D163E mutation), 113 nM (TNK2, R806Q mutation) 1體外研究 XMD8-87 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effecton the control cells out to the highest tested concentrations (1,000
4、 nM). XMD8-87 has IC50s of 38 nM and113 nM for the D163E and R806Q mutations. The effects of XMD8-87 on TNK2 cell lines are largely due toon-target effects on TNK2. Auto-phosphorylation of overexpressed TNK2 mutants could be blocked withTNK2 inhibitor XMD8-87 1.PROTOCOLKinase Assay 1 Kinase targets
5、are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase ProfilingService to determine IC50 values. The compounds (XMD8-87) are assayed at 10 concentrations (3-foldserial dilutions starting from 1 M) at an ATP concentration equal to the ATP Km 1.MCE has not independently con
6、firmed the accuracy of these methods. They are for reference only.Cell Assay 1 Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM-100, XMD8-87 and XMD16-5. Cellviability is measured using a methanethiosulfonate (MTS)-based assay and absorbance (490 nm) is read at 1and 3 hou
7、rs after adding reagent 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration ofKinase Inhibitor Screening and Genomic Analysis.McePdfHeightCaution: Product has not been fully validated for medical applications.For research
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年收費(fèi)的生產(chǎn)服務(wù)項(xiàng)目資金籌措計(jì)劃書(shū)代可行性研究報(bào)告
- 《疾病常識(shí)講解》課件
- 湖北省宜昌市部分省級(jí)示范高中2024-2025學(xué)年高一下學(xué)期期中考試語(yǔ)文試卷
- 2024年籃球裁判員的自我練習(xí)方法試題及答案
- 《胃癌的CT診斷》課件
- 窮人面試真題及答案
- 掌握模具設(shè)計(jì)理論試題及答案
- 籃球裁判員考核標(biāo)準(zhǔn)與試題及答案
- 《探討肥胖問(wèn)題》課件
- 經(jīng)??碱}農(nóng)業(yè)植保員考試試題及答案
- 圍手術(shù)期下肢靜脈血栓預(yù)防與護(hù)理
- 貴州省氣象部門(mén)招聘考試真題2024
- 《大學(xué)生就業(yè)指導(dǎo)》期末筆記
- 《訴衷情》(陸游)課件
- 陜西省2024年中考語(yǔ)文現(xiàn)代文閱讀真題
- 2025屆高考語(yǔ)文二輪復(fù)習(xí):文言文知識(shí)點(diǎn)與答題技巧匯編 講義
- Unit 5 Here and now Section A Grammar 說(shuō)課稿 2023-2024學(xué)年人教版英語(yǔ)七年級(jí)下冊(cè)
- 地下綜合管廊建設(shè)項(xiàng)目可行性研究報(bào)告
- 基于多源異構(gòu)數(shù)據(jù)的地質(zhì)知識(shí)圖譜構(gòu)建與應(yīng)用
- 2024年戰(zhàn)略規(guī)劃咨詢服務(wù)合同
- 2024年領(lǐng)導(dǎo)干部任前廉政知識(shí)考試測(cè)試題庫(kù)及答案
評(píng)論
0/150
提交評(píng)論